Morgan Stanley starts GSK stock with underweight rating
Morgan Stanley (NYSE:MS) initiated coverage on shares of GlaxoSmithKline (NYSE:GSK:LN) (NYSE: GSK), a $72.5 billion pharmaceutical giant with a 25-year track record of consistent dividend payments, ...
GSK initiated with an Equal Weight at Morgan Stanley
Morgan Stanley initiated coverage of GSK (GSK) with an Equal Weight rating and 1,450 GBp price target The shares trade at an inexpensive ...
Royalty Pharma Announces R&D Funding Collaboration With Biogen
We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...
Drug developer GSK leaving 635K sf life sciences lab near DC
Drug developer GSK is vacating its 635,000-square-foot life sciences lab in Rockville, Maryland, where it was the sole tenant ...
Fierce Biotech23h
GSK plans to move vaccine R&D center from Rockville, Maryland, to the Boston area
After calling Rockville, Maryland, home for more than eight years, Big Pharma GSK is planning to move its vaccine and ...
Indiatimes1d
GSK Pharma - GlaxoSmithKline Pharmaceuticals Share Price
GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...